- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
(1) Registration Statement (FormS-3No. 333-213495) of Intra-Cellular Therapies, Inc.,
(2) Registration Statement (FormS-8No. 333-205070) of Intra-Cellular Therapies, Inc. pertaining to the Intra-Cellular Therapies, Inc. Amended and Restated 2013 Equity Incentive Plan,
(3) Registration Statement (Post-Effective Amendment No. 3 to FormS-1 on FormS-3No. 333-191238) of Intra-Cellular Therapies, Inc., and
(4) Registration Statement (FormS-8No. 333-193310) of Intra-Cellular Therapies, Inc. pertaining to the ITI, Inc. 2003 Equity Incentive Plan, as amended, and the Intra-Cellular Therapies, Inc. Amended and Restated 2013 Equity Incentive Plan;
of our reports dated March 1, 2018, with respect to the consolidated financial statements of Intra-Cellular Therapies, Inc. and the effectiveness of internal control over financial reporting of Intra-Cellular Therapies, Inc. included in this Annual Report (Form10-K) of Intra-Cellular Therapies, Inc. for the year ended December 31, 2017.
/s/ Ernst & Young LLP |
Baltimore, MD |
March 1, 2018 |